Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

Immuron partnered with the U.S. Uniformed Services University to initiate clinical trials for its lead oral candidate IMM‑124E (same as Travelan®), advancing efforts to gain FDA approval for treating acute gastrointestinal pathogens—typically referred to as “stomach bugs.” This move marked a significant regulatory milestone for the company, signaling its transition from OTC supplementation toward formal drug approval pathways in the U.S.

The Market Online: Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment